Watson Confirms Atelvia Patent Challenge

Watson Pharmaceuticals, Inc.

today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Risedronate Sodium Delayed-release Tablets, 35 mg.  Watson's Risedronate Sodium Delayed-release Tablets are a generic version of Warner Chilcott , LLC's Atelvia delayed-release tablets. Atelvia is indicated for the treatment of postmenopausal osteoporosis.